Patents

Gilead wins $69 million and an injunction against HIV counterfeiters

A New York federal judge adopted a magistrate's findings against eight people and 18 shell companies that refilled real Biktarvy bottles with other medicines and resold them under Gilead's trademarks

By Mattia Sapere
5 min read

ShareLinkedInFacebookX

text
Photo: Andrew Dawes / Unsplash

Gilead Sciences has won more than $69 million in damages and a permanent injunction against a network that refilled genuine HIV medicine bottles with other drugs and sold them to pharmacies around New York City under its trademarks. U.S. District Judge Natasha Merle of the Eastern District of New York adopted a magistrate judge's findings in a default judgment against eight individuals and 18 shell companies. The ruling is the second civil case the company has brought over counterfeit versions of Biktarvy and Descovy, and it is an intellectual property case before it is a medicines case: the claim rests on the labels, the seals and the brand.

A default judgment against 26 defendants who never answered

The order came from U.S. District Judge Natasha Merle. She adopted a report and recommendation entered on 28 October by U.S. Magistrate Judge Joseph Marutollo, which granted Gilead's motion for default judgment against eight individuals and 18 shell companies. None of the defendants contested the claims, so the magistrate treated the complaint's allegations as true. The corporate defendants were all pharmaceutical distributors registered as New York domestic corporations, which gave the court general jurisdiction over them; the individuals were held to be within reach for business transacted in New York. The award exceeds $69 million, and the injunction bars the defaulting defendants from selling Gilead-branded medicines. The case is the second Gilead has brought against a major ring reselling HIV treatments to pharmacies in the New York area, as first reported by IPWatchdog.

“The patent system was designed to incentivize genuine innovation. Right now, it is not just incentivizing innovation. It is incentivizing manipulation.”

— Merith Basey, chief executive of Patients for Affordable Drugs Now, at the Senate Judiciary Committee hearing

Bottles bought on the street, emptied, resealed and pedigreed

In the complaint filed in June 2024, Gilead described a supply scheme built on second-hand packaging. The conspirators acquired authentic bottles of Biktarvy and Descovy, typically by buying them off the street from patients who could be persuaded to give up their medication for cash. The bottles were emptied, filled with other medicines, stripped of patient information and closed again with fake versions of Gilead's tamper-evident seal. They were then sold to pharmacies with counterfeit pedigrees, the documents meant to trace a medicine's chain of sale.

Close-up of one hundred dollar bills Photo: Giorgio Trovato / Unsplash

Read also on The Patent: Supreme Court leaves Federal Circuit rule on patent equivalents intact · GAO Warns USPTO Backlog Targets Risk Failure Under Staff Strain

At the top of the ring, according to the allegations, were Boris Aminov and Antonio Payano, both New York City residents. Aminov acted as an off-the-books principal for several of the shell distributors, the magistrate noted, while other conspirators signed as nominal paper principals. Both men had already pleaded guilty to conspiracy to commit healthcare fraud in a separate Department of Justice case in the Southern District of New York. Another defendant, Aminov's mother, allegedly ran retail pharmacies that recruited patients to fill HIV prescriptions for the ring.

Why the Lanham Act covered a bottle of the wrong pills

No patent was at issue here. Gilead sued under the Lanham Act, the U.S. federal statute on trademarks, citing 15 U.S.C. § 1114(1). Magistrate Judge Marutollo found that the company had pleaded both of its causes of action: unauthorized use of a registered trademark, and unauthorized use of a mark applied to product labelling.

The evidence went beyond the fake sale documents. Counterfeit bottles held the wrong pills, patient information sheets were reproduced fraudulently and replica seals made packaging look unopened. In counterfeiting cases, the magistrate wrote, the Polaroid test for likelihood of consumer confusion does not need to be applied factor by factor, because the sale of counterfeit branded goods is already established. The order adopted his conclusion that liability was indisputable on these facts.

Profits per bottle, trebled for willfulness

Gilead's damages expert estimated the profit the company would have made on each counterfeit bottle, using conservative unit-sales figures drawn from sales through online pharmacy-to-pharmacy marketplaces and from products subject to Medicaid rebates. The magistrate recommended that Aminov and Payano be held jointly and severally liable for lost profits, and that Ivan Ohar be held jointly and severally liable for the profits earned through shell companies he operated. Judge Merle's order also adopted the finding that damages should be trebled because the conduct was willful, and the magistrate noted that civil penalties remained available even though several defendants had been ordered to pay restitution in the parallel criminal proceedings.

The file also records where some of the money went: one defendant used proceeds to buy two waterfront properties in the Bronx and a Mercedes-Benz Maybach, which retails for around $200,000. Peter Khaim, the owner of commercial properties used by Ohar's companies, was not among the defaulting defendants.

The same week, senators argued about patent thickets

Counterfeiting was not the only intellectual property argument in Washington. The full Senate Judiciary Committee held a hearing titled "Prescribing Sunshine: How Competition & Transparency Lowers Prescription Drug Costs", with five witnesses and no pharmaceutical company or patent owner among them.

Merith Basey, chief executive of Patients for Affordable Drugs Now, pressed senators to pass a package of bills together rather than one at a time. The list includes the Affordable Prescriptions for Patients Act (S.1041), sponsored by Senator John Cornyn, which targets so-called patent thicketing, and the ETHIC Act (S.2276), from Senator Peter Welch, which would limit a patent owner to asserting one patent from the same patent group in an infringement action. Patent thicketing is a disputed term for multiple patents covering one drug, which critics say slows generic and biosimilar entry; the Council for Innovation Promotion has called that account misleading. Senator John Kennedy of Louisiana took the other side of the investment argument, telling the committee that companies risking capital on drug development are entitled to recoup costs and a fair return.

AI-assisted article